Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Selective inhibition of CCR7- TEM cells activation by a novel peptide targeting Kv1.3 in a rat EAE model.
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
Glatiramer acetate during early pregnancy: A prospective cohort study.
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.
Cyclophosphamide
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
[Neuromyelitis optica following thymectomy with severe spinal cord atrophy after frequent relapses for 30 years].
Pathological mechanisms in progressive multiple sclerosis.
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
The correlation between symptomatic fatigue to definite measures of gait in people with multiple sclerosis.
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Glatiramer acetate treatment negatively regulates type I interferon signaling.

Pages